IL32 and cancer: Importantly, β5‐integrin is recognized as the putative binding receptor for IL32.[12, 20] In contrast, the IL32‐negative pericyte subset exhibited a weaker association with cancer cells compared to the IL32‐positive pericyte subset and did not show enrichment in pathways observed in the IL32‐positive subset, particularly those related to EGFR tyrosine kinase inhibitor resistance.